John A. Dawson, CBE, is an eminent and widely-respected figure in the healthcare sector who consults for the Vulpes Life Sciences Fund.
As former Chief Executive Officer of Oxford Biomedica, he was recognized for his outstanding leadership in delivering the life-saving Oxford AstraZeneca COVID-19 vaccine with unprecedented speed in 2021. During his 13-year tenure at Oxford Biomedica, the business grew into a global leader in viral vector technologies for cell and gene therapy, resulting in it entering the FTSE 250 index in 2020.
John currently serves as a non-executive director at Ergomed, a specialized provider of services to the pharmaceutical industry, Chinese Speciality Pharma Ltd., a company that brings innovative specialty and rare disease products to China, Norgine, a leading European specialist pharmaceutical company that has been committed to bringing transformative products to patients for over a century, and Virocell, a gene therapy manufacturing company
Prior to his tenure at Oxford Biomedica, John held several senior executive roles, including Managing Director for Europe at Cephalon, Inc., and Financial Director for Serono UK. Mr. Dawson is a Chartered Accountant and holds a BSc in Mathematics from Swansea University.